

## Xenomics

[View the current Xenomics Page on BioPortfolio.com](http://www.bioportfolio.com/biocorporate/32627-Xenomics.html)

(<http://www.bioportfolio.com/biocorporate/32627-Xenomics.html>)

### Contact Details:

**420 Lexington Avenue Suite 170**

**New York**

**New York**

**10170**

**United States of America**

Tel: (212) 297-0808

Fax: (212) 297-1888

Email: [info@xenomics.com](mailto:info@xenomics.com)

Xenomics, Inc. is the developer of next-generation molecular diagnostics products that address important health problems worldwide. Our mission is to apply our proprietary transrenal DNA test platform to develop highly sensitive, truly non-invasive molecular diagnostics that replace outdated blood, sputum, and tissue testing technologies many of which are not sufficiently sensitive and specific, and are often hazardous, and difficult to automate. The patented technology uses simple urine specimens and can be applied to a broad range of products addressing multi-billion dollar markets including infectious disease detection and monitoring, cancer detection and monitoring, prenatal genetic testing, monitoring organ/cell transplants, human forensics, and biodefense. Xenomics has made continuing progress in its clinical studies in infectious disease testing, particularly in the field of TB detection and therapeutic monitoring, HIV proviral DNA detection, and detection of early cancer genetic markers.

### Recent Publications by Xenomics:



- [Transrenal DNA testing: progress and perspectives.](#)

*Transrenal DNA (Tr-DNA) is a recently discovered class of extracellular...*30th June, 2006  
Xenomics Inc., Monmouth- Expert Rev Mol Diagn. 2006 Mar;6(2):153-63. ([DOI Direct Link](#))

- [Apoptosis in the myocardium: much is still expected.](#)

*Apoptosis continues to be a controversial concept and subject of debate...*2nd May, 2006  
Xenomics, Inc., Richmond, CA 94805, USA.- Expert Opin Ther Targets. 2003 Feb;7(1):61-9. ([DOI Direct Link](#))

**BioCorporate Profiles - upgrade to a full profile**

BioPortfolio's BioCorporate full profiles offers your organization the opportunity to increase internet traffic to your corporate web site and enhance awareness of your business, technology, products and services. BioCorporate profiles are dynamic and are updated weekly with new information sourced from core information resources: publications, clinical trials, patents and global news.

Why you should upgrade your BioPortfolio BioCorporate profile:

- the ability to amend and add information on products and services to your profile using a membership username and password
- the option to add a corporate logo
- the creation of high value URL links back to your organization's website which will improve search engine ranking - resulting in increased site traffic
- the option have your press releases published on BioPortfolio and distributed via our BioNewsCast service
- an enhanced BioCorporate profile will also improve your exposure on BioPortfolio's relate service indepth.

The annual cost is \$495.00 for established organizations and \$295.00 for organizations less than 12 months old.

\*\*\*

Resources from the [NCBI](#) used in this document, [NCBI's standard disclaimer applies](#).

Nothing in this document should be used in place of personal medical advice from your own qualified medical practitioner. See BioPortfolio.com [User Agreement](#)

Send comments and feedback to:

Peter Barfoot Managing Director, BioPortfolio Ltd.

UK Tel: (+44) 1300 321501

USA Voicemail and Fax: (+1) 415 680 2472

[Peter Barfoot peter.barfoot@bioportfolio.com](mailto:peter.barfoot@bioportfolio.com)

All rights reserved. All other trademarks recognized.

BioPortfolio Limited is registered in England & Wales at Wessex Barn, Dorchester Road, Frampton, Dorset, DT2 9NB, UK. No.3312883 VAT No. GB 744 6483 10

Copyright 1997-2008 - BioPortfolio Limited.

